Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul 14;108(8):e644-e645.
doi: 10.1210/clinem/dgad096.

Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial"

Pierre Chatelain  1 , Mads Kjelgaard-Hansen  2 , Kennett Sprogøe  2
Affiliations
Comment

Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial"

Pierre Chatelain et al. J Clin Endocrinol Metab. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Miller BS, Blair JC, Rasmussen MH, et al. . Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107(12):3378‐3388. - PMC - PubMed
    1. Chatelain P, Malievskiy O, Radziuk K, et al. . A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency. J Clin Endocrinol Metab. 2017;102(5):1673‐1682. - PubMed
    1. Miller BS. What do we do now that the long-acting growth hormone is here? Front Endocrinol. 2022;13:980979. - PMC - PubMed
    1. Thornton PS, Maniatis AK, Aghajanova E, et al. . Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 heiGHt trial. J Clin Endocrinol Metab. 2021;106(11):3184‐3195. - PMC - PubMed
    1. Ascendis Pharma . Press release: positive results from VISEN's phase 3 trial of once-weekly TransCon hGH in China consistent with Ascendis Pharma's phase 3 heiGHt trial. 2022. https://investors.ascendispharma.com/static-files/7b7cd7ff-fcb6-4b46-bf6.... Accessed 3 January, 2023.

MeSH terms